Single dose GLP toxicity and biodistribution study of a conditionally replicative adenovirus vector, CRAd-S-pk7, administered by intracerebral injection to Syrian hamsters

Julius Woongki Kim, Brenda Auffinger, Drew A. Spencer, Jason Miska, Alan L. Chang, Joshua Robert Kane, Jacob S. Young, Deepak Kanojia, Jian Qiao, Jill F. Mann, Lingjiao Zhang, Meijing Wu, Atique U. Ahmed, Karen S. Aboody, Theresa V. Strong, Charles D. Hébert, Maciej S. Lesniak

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: CRAd-S-pk7 is a conditionally replicative oncolytic adenoviral vector that contains a survivin promoter and a pk7 fiber modification that confer tumor-specific transcriptional targeting and preferential replication in glioma while sparing the surrounding normal brain parenchyma. Methods: This IND-enabling study performed under GLP conditions evaluated the toxicity and biodistribution of CRAd-S-pk7 administered as a single intracerebral dose to Syrian hamsters, a permissive model of adenoviral replication. Two hundred and forty animals were stereotactically administered either vehicle (n = 60) or CRAd-S-pk7 at 2.5 × 107, 2.5 × 108, or 2.5 × 109 viral particles (vp)/animal (each n = 60) on day 1. The animals were closely monitored for toxicology evaluation, assessment of viral distribution, and immunogenicity of CRAd-S-pk7. Results: Changes in hematology, clinical chemistry, and coagulation parameters were minor and transient, and consistent with the inflammatory changes observed microscopically. These changes were considered to be of little toxicological significance. The vector remained localized primarily in the brain and to some degree in the tissues at the incision site. Low levels of vector DNA were detected in other tissues in a few animals suggesting systemic circulation of the virus. Viral DNA was detected in brains of hamsters for up to 62 days. However, microscopic changes and virus-related toxicity to the central nervous system were considered minor and decreased in incidence and severity over time. Such changes are not uncommon in studies using adenoviral vectors. Conclusion: This study provides safety and toxicology data justifying a clinical trial of CRAd-S-pk7 loaded in FDA-approved HB1.F3.CD neural stem cell carriers administered at the tumor resection bed in humans with recurrent malignant glioma.

Original languageEnglish (US)
Article number134
JournalJournal of Translational Medicine
Volume14
Issue number1
DOIs
StatePublished - May 16 2016

Fingerprint

Mesocricetus
Adenoviridae
Toxicity
Animals
Toxicology
Brain
Injections
Viruses
Glioma
Tumors
Tissue
Clinical Chemistry
Neural Stem Cells
Viral DNA
Neurology
Hematology
Coagulation
Stem cells
Cricetinae
Virion

Keywords

  • Biodistribution
  • Conditionally replicative adenovirus
  • CRAd-S-pk7
  • Immune response
  • Oncolytic adenovirus
  • Toxicity

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Single dose GLP toxicity and biodistribution study of a conditionally replicative adenovirus vector, CRAd-S-pk7, administered by intracerebral injection to Syrian hamsters. / Kim, Julius Woongki; Auffinger, Brenda; Spencer, Drew A.; Miska, Jason; Chang, Alan L.; Kane, Joshua Robert; Young, Jacob S.; Kanojia, Deepak; Qiao, Jian; Mann, Jill F.; Zhang, Lingjiao; Wu, Meijing; Ahmed, Atique U.; Aboody, Karen S.; Strong, Theresa V.; Hébert, Charles D.; Lesniak, Maciej S.

In: Journal of Translational Medicine, Vol. 14, No. 1, 134, 16.05.2016.

Research output: Contribution to journalArticle

Kim, JW, Auffinger, B, Spencer, DA, Miska, J, Chang, AL, Kane, JR, Young, JS, Kanojia, D, Qiao, J, Mann, JF, Zhang, L, Wu, M, Ahmed, AU, Aboody, KS, Strong, TV, Hébert, CD & Lesniak, MS 2016, 'Single dose GLP toxicity and biodistribution study of a conditionally replicative adenovirus vector, CRAd-S-pk7, administered by intracerebral injection to Syrian hamsters', Journal of Translational Medicine, vol. 14, no. 1, 134. https://doi.org/10.1186/s12967-016-0895-8
Kim, Julius Woongki ; Auffinger, Brenda ; Spencer, Drew A. ; Miska, Jason ; Chang, Alan L. ; Kane, Joshua Robert ; Young, Jacob S. ; Kanojia, Deepak ; Qiao, Jian ; Mann, Jill F. ; Zhang, Lingjiao ; Wu, Meijing ; Ahmed, Atique U. ; Aboody, Karen S. ; Strong, Theresa V. ; Hébert, Charles D. ; Lesniak, Maciej S. / Single dose GLP toxicity and biodistribution study of a conditionally replicative adenovirus vector, CRAd-S-pk7, administered by intracerebral injection to Syrian hamsters. In: Journal of Translational Medicine. 2016 ; Vol. 14, No. 1.
@article{05a68fa5b3534bdf988687c585d0937e,
title = "Single dose GLP toxicity and biodistribution study of a conditionally replicative adenovirus vector, CRAd-S-pk7, administered by intracerebral injection to Syrian hamsters",
abstract = "Background: CRAd-S-pk7 is a conditionally replicative oncolytic adenoviral vector that contains a survivin promoter and a pk7 fiber modification that confer tumor-specific transcriptional targeting and preferential replication in glioma while sparing the surrounding normal brain parenchyma. Methods: This IND-enabling study performed under GLP conditions evaluated the toxicity and biodistribution of CRAd-S-pk7 administered as a single intracerebral dose to Syrian hamsters, a permissive model of adenoviral replication. Two hundred and forty animals were stereotactically administered either vehicle (n = 60) or CRAd-S-pk7 at 2.5 × 107, 2.5 × 108, or 2.5 × 109 viral particles (vp)/animal (each n = 60) on day 1. The animals were closely monitored for toxicology evaluation, assessment of viral distribution, and immunogenicity of CRAd-S-pk7. Results: Changes in hematology, clinical chemistry, and coagulation parameters were minor and transient, and consistent with the inflammatory changes observed microscopically. These changes were considered to be of little toxicological significance. The vector remained localized primarily in the brain and to some degree in the tissues at the incision site. Low levels of vector DNA were detected in other tissues in a few animals suggesting systemic circulation of the virus. Viral DNA was detected in brains of hamsters for up to 62 days. However, microscopic changes and virus-related toxicity to the central nervous system were considered minor and decreased in incidence and severity over time. Such changes are not uncommon in studies using adenoviral vectors. Conclusion: This study provides safety and toxicology data justifying a clinical trial of CRAd-S-pk7 loaded in FDA-approved HB1.F3.CD neural stem cell carriers administered at the tumor resection bed in humans with recurrent malignant glioma.",
keywords = "Biodistribution, Conditionally replicative adenovirus, CRAd-S-pk7, Immune response, Oncolytic adenovirus, Toxicity",
author = "Kim, {Julius Woongki} and Brenda Auffinger and Spencer, {Drew A.} and Jason Miska and Chang, {Alan L.} and Kane, {Joshua Robert} and Young, {Jacob S.} and Deepak Kanojia and Jian Qiao and Mann, {Jill F.} and Lingjiao Zhang and Meijing Wu and Ahmed, {Atique U.} and Aboody, {Karen S.} and Strong, {Theresa V.} and H{\'e}bert, {Charles D.} and Lesniak, {Maciej S.}",
year = "2016",
month = "5",
day = "16",
doi = "10.1186/s12967-016-0895-8",
language = "English (US)",
volume = "14",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Single dose GLP toxicity and biodistribution study of a conditionally replicative adenovirus vector, CRAd-S-pk7, administered by intracerebral injection to Syrian hamsters

AU - Kim, Julius Woongki

AU - Auffinger, Brenda

AU - Spencer, Drew A.

AU - Miska, Jason

AU - Chang, Alan L.

AU - Kane, Joshua Robert

AU - Young, Jacob S.

AU - Kanojia, Deepak

AU - Qiao, Jian

AU - Mann, Jill F.

AU - Zhang, Lingjiao

AU - Wu, Meijing

AU - Ahmed, Atique U.

AU - Aboody, Karen S.

AU - Strong, Theresa V.

AU - Hébert, Charles D.

AU - Lesniak, Maciej S.

PY - 2016/5/16

Y1 - 2016/5/16

N2 - Background: CRAd-S-pk7 is a conditionally replicative oncolytic adenoviral vector that contains a survivin promoter and a pk7 fiber modification that confer tumor-specific transcriptional targeting and preferential replication in glioma while sparing the surrounding normal brain parenchyma. Methods: This IND-enabling study performed under GLP conditions evaluated the toxicity and biodistribution of CRAd-S-pk7 administered as a single intracerebral dose to Syrian hamsters, a permissive model of adenoviral replication. Two hundred and forty animals were stereotactically administered either vehicle (n = 60) or CRAd-S-pk7 at 2.5 × 107, 2.5 × 108, or 2.5 × 109 viral particles (vp)/animal (each n = 60) on day 1. The animals were closely monitored for toxicology evaluation, assessment of viral distribution, and immunogenicity of CRAd-S-pk7. Results: Changes in hematology, clinical chemistry, and coagulation parameters were minor and transient, and consistent with the inflammatory changes observed microscopically. These changes were considered to be of little toxicological significance. The vector remained localized primarily in the brain and to some degree in the tissues at the incision site. Low levels of vector DNA were detected in other tissues in a few animals suggesting systemic circulation of the virus. Viral DNA was detected in brains of hamsters for up to 62 days. However, microscopic changes and virus-related toxicity to the central nervous system were considered minor and decreased in incidence and severity over time. Such changes are not uncommon in studies using adenoviral vectors. Conclusion: This study provides safety and toxicology data justifying a clinical trial of CRAd-S-pk7 loaded in FDA-approved HB1.F3.CD neural stem cell carriers administered at the tumor resection bed in humans with recurrent malignant glioma.

AB - Background: CRAd-S-pk7 is a conditionally replicative oncolytic adenoviral vector that contains a survivin promoter and a pk7 fiber modification that confer tumor-specific transcriptional targeting and preferential replication in glioma while sparing the surrounding normal brain parenchyma. Methods: This IND-enabling study performed under GLP conditions evaluated the toxicity and biodistribution of CRAd-S-pk7 administered as a single intracerebral dose to Syrian hamsters, a permissive model of adenoviral replication. Two hundred and forty animals were stereotactically administered either vehicle (n = 60) or CRAd-S-pk7 at 2.5 × 107, 2.5 × 108, or 2.5 × 109 viral particles (vp)/animal (each n = 60) on day 1. The animals were closely monitored for toxicology evaluation, assessment of viral distribution, and immunogenicity of CRAd-S-pk7. Results: Changes in hematology, clinical chemistry, and coagulation parameters were minor and transient, and consistent with the inflammatory changes observed microscopically. These changes were considered to be of little toxicological significance. The vector remained localized primarily in the brain and to some degree in the tissues at the incision site. Low levels of vector DNA were detected in other tissues in a few animals suggesting systemic circulation of the virus. Viral DNA was detected in brains of hamsters for up to 62 days. However, microscopic changes and virus-related toxicity to the central nervous system were considered minor and decreased in incidence and severity over time. Such changes are not uncommon in studies using adenoviral vectors. Conclusion: This study provides safety and toxicology data justifying a clinical trial of CRAd-S-pk7 loaded in FDA-approved HB1.F3.CD neural stem cell carriers administered at the tumor resection bed in humans with recurrent malignant glioma.

KW - Biodistribution

KW - Conditionally replicative adenovirus

KW - CRAd-S-pk7

KW - Immune response

KW - Oncolytic adenovirus

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=84968754667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84968754667&partnerID=8YFLogxK

U2 - 10.1186/s12967-016-0895-8

DO - 10.1186/s12967-016-0895-8

M3 - Article

C2 - 27184224

AN - SCOPUS:84968754667

VL - 14

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

IS - 1

M1 - 134

ER -